Clinical Meaning in Skin-specific Quality of Life Instruments: A Comparison of the Dermatology Life Quality Index and Skindex Banding Systems

Dermatologic Clinics

Volumn 30, Issue 2, 2012, Pages 333-342

  Rogers, Anna ^a   DeLong, Laura K ^b,c   Chen, Suephy C ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY CLINIC   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Clinical meaning; Dermatology; Quality of life

Indexed keywords

CLINICAL ASSESSMENT TOOL; CLINICAL DECISION MAKING; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; EMOTION; HEALTH STATUS; HUMAN; INTERMETHOD COMPARISON; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE INDEX; QUESTIONNAIRE; REVIEW; SCORING SYSTEM; SHORT FORM 36; SKIN DISEASE; SKINDEX; WELLBEING;

DERMATOLOGY; HEALTH STATUS; HUMANS; QUALITY OF LIFE; QUESTIONNAIRES; SKIN DISEASES; TREATMENT OUTCOME;

EID: 84863041776     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2011.11.010     Document Type: Review

References (44)

1. Division of mental health and prevention of substance abuse world health organization 1997, WHOQOL Measuring Quality of Life, Available at:, Accessed July 18, 2011. http://www.who.int/mental_health/media/68.pdf.
2. Chren M.M., Lasek R.J., Quinn L.M., et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. JInvest Dermatol 1996, 107(5):707-713.
3. Salek M.S., Finlay A.Y., Luscombe D.K., et al. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double-blind, placebo-controlled trial. Br J Dermatol 1993, 129(4):422-430.
4. Motley R.J., Finlay A.Y. Practical use of a disability index in the routine management of acne. Clin Exp Dermatol 1992, 17(1):1-3.
5. Schmitt J.M., Ford D.E. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006, 213(2):102-110.
6. Finlay A.Y., Khan G.K. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994, 19(3):210-216.
7. Loo W.J., Diba V., Chawla M., et al. Dermatology Life Quality Index: influence of an illustrated version. Br J Dermatol 2003, 148(2):279-284.
8. Basra M.K., Sue-Ho R., Finlay A.Y. The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease. Br J Dermatol 2007, 156(3):528-538. [Erratum appears in: Br J Dermatol 2007;156(4):791].
9. Holme S.A., Man I., Sharpe J.L., et al. The Children's Dermatology Life Quality Index: validation of the cartoon version. Br J Dermatol 2003, 148(2):285-290.
10. Basra M.K., Fenech R., Gatt R.M., et al. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008, 159(5):997-1035.
11. Lewis V., Finlay A.Y. 10 years experience of the Dermatology Life Quality Index (DLQI). JInvestig Dermatol Symp Proc 2004, 9(2):169-180. [review].
12. Hongbo Y., Thomas C.L., Harrison M.A., et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean?. JInvest Dermatol 2005, 125(4):659-664.
13. Evers A.W., Duller P., van de Kerkhof P.C., et al. The Impact of Chronic Skin Disease on Daily Life (ISDL), 2008 Disease on Daily Life (ISDL): a generic and dermatology-specific health instrument. Br J Dermatol 2008, 158(1):101-108.
14. Both H., Essink-Bot M.L., Busschbach J., et al. Critical review of generic and dermatology-specific health-related quality of life instruments. JInvest Dermatol 2007, 127(12):2726-2739.
15. Ware J.E. SF-36 health survey update. Spine (Phila Pa 1976) 2000, 25(24):3130-3139. [review].
16. De Korte J., Mombers F.M., Sprangers M.A., et al. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol 2002, 138(9):1221-1227. [review], [discussion: 1227].
17. Chren M.M., Lasek R.J., Flocke S.A., et al. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997, 133(11):1433-1440.
18. Chren M.M., Lasek R.J., Sahay A.P., et al. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. JCutan Med Surg 2001, 5(2):105-110.
19. Nijsten T.E., Sampogna F., Chren M.M., et al. Testing and reducing skindex-29 using Rasch analysis: Skindex-17. JInvest Dermatol 2006, 126(6):1244-1250.
20. Jaeschke R., Singer J., Guyatt G.H. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989, 10(4):407-415.
21. Crosby R.D., Kolotkin R.L., Williams G.R. Defining clinically meaningful change in health-related quality of life. JClin Epidemiol 2003, 56(5):395-407.
22. Guyatt G.H., Osoba D., Wu A.W., Clinical Significance Consensus Meeting Group, et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002, 77(4):371-383. [review].
23. Finlay A.Y. Current severe psoriasis and the rule of tens. Br J Dermatol 2005, 152(5):861-867. [review].
24. Mrowietz U., Kragballe K., Reich K., et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011, 303(1):1-10.
25. Mease P.J., Ory P., Sharp J.T., et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009, 68(5):702-709.
26. MacDonald A., Burden A.D. Psoriasis: advances in pathophysiology and management. Postgrad Med J 2007, 83(985):690-697. [review].
27. Lee R.A., Dommasch E., Treat J., et al. Aprospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. JAm Acad Dermatol 2009, 60(4):565-573.
28. Woods M.T., Brown P.A., Baig-Lewis S.F., et al. Effects of a novel formulation of fluocinonide 0.1% cream on skin barrier function in atopic dermatitis. JDrugs Dermatol 2011, 10(2):171-176.
29. Haeck I.M., Knol M.J., Ten Berge O., et al. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. JAm Acad Dermatol 2011, 64(6):1074-1084.
30. Magerl M., Pisarevskaja D., Scheufele R., et al. Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: a prospective trial. Allergy 2010, 65(1):78-83.
31. Rehn L.M., Meririnne E., Höök-Nikanne J., et al. Depressive symptoms and suicidal ideation during isotretinoin treatment: a 12-week follow-up study of male Finnish military conscripts. JEur Acad Dermatol Venereol 2009, 23(11):1294-1297.
32. Potter P.C., Kapp A., Maurer M., et al. Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy 2009, 64(4):596-604.
33. Szepietowski J.C., Balaskas E., Taube K.M., Uraemic Xerosis Working Group, et al. Quality of life in patients with uraemic xerosis and pruritus. Acta Derm Venereol 2011, 91(3):313-317.
34. Hald M., Agner T., Blands J., et al. Quality of life in a population of patients with hand eczema: a six-month follow-up study. Acta Derm Venereol 2011, 91(4):484-486.
35. Huang Y.H., Yang C.H., Chen Y.H., et al. Reduction in osmidrosis using a suction-assisted cartilage shaver improves the quality of life. Dermatol Surg 2010, 36(10):1573-1577.
36. Stafford R., Farrar M.D., Kift R., et al. The impact of photosensitivity disorders on aspects of lifestyle. Br J Dermatol 2010, 163(4):817-822.
37. Szepietowski J.C., Reich A., Wesołowska-Szepietowska E., for the National Quality of Life in Dermatology Group, et al. Quality of life in patients suffering from seborrheic dermatitis: influence of age, gender and education level. Mycoses 2009, 52(4):357-363.
38. Nijsten T., Sampogna F., Abeni D. Categorization of Skindex-29 scores using mixture analysis. Dermatology 2009, 218(2):151-154.
39. Prinsen C.A., Lindeboom R., Sprangers M.A., et al. Health-related quality of life assessment in dermatology: interpretation of Skindex-29 scores using patient-based anchors. JInvest Dermatol 2010, 130(5):1318-1322.
40. Prinsen C.A., Lindeboom R., de Korte J. Interpretation of Skindex-29 scores: cutoffs for mild, moderate, and severe impairment of health-related quality of life. JInvest Dermatol 2011, 131(9):1945-1947.
41. Dunbar S., McCombs K., DeLong L.K., et al. Banding and the clinical interpretation of Skindex-29 scores using an anchor based technique. JAm Acad Dermatol 2010, 62(3):AB68.
42. Requena L., Yus E.S., Kutzner H. Panniculitis. Fitzpatrick's dermatology in general medicine 2008, McGraw-Hill, New York, Chapter 68. Available at:, Accessed December 13, 2011. http://www.accessmedicine.com/content.aspx%3FaID%3d2978288, 7th edition. K. Wolff, L.A. Goldsmith, S.I. Katz (Eds.).
43. Shikiar R., Willian M.K., Okun M.M., et al. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006, 4:71.
44. Shikiar R., Harding G., Leahy M., et al. Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria. Health Qual Life Outcomes 2005, 3:36.